SGLT2 inhibitors are associated with weight loss, which can positively impact cardiovascular risk factors such as insulin resistance and inflammation [25]. Some studies have suggested that SGLT2 inhibitors can improve endothelial function, potentially reducing atherosclerotic progression [26]. This evidence concerns the gene SLC5A2 and Insulin resistance.